Scientific article
English

Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo

Published in

Diabetes, obesity & metabolism, vol. 13, no. 4, p. 326-336

Publication date

2011

Abstract

Glucagon-like peptide-1 (GLP-1) has protective effects on pancreatic β-cells. We evaluated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, on β-cells in vitro and in vivo.

Keywords

  • Animals
  • Apoptosis
  • Cells, Cultured
  • Deoxyuridine/analogs & derivatives
  • Diabetes Mellitus, Type 2/drug therapy/pathology
  • Glucagon-Like Peptide 1/administration & dosage/analogs & derivatives/pharmacology
  • Humans
  • Immunohistochemistry
  • Insulin-Secreting Cells/drug effects/pathology/physiology
  • Male
  • Peptides/administration & dosage/pharmacology
  • Rats
  • Rats, Zucker
  • Receptors, Glucagon/administration & dosage

Citation (ISO format)

UHLES, S et al. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo. In: Diabetes, obesity & metabolism, 2011, vol. 13, n° 4, p. 326–336. doi: 10.1111/j.1463-1326.2010.01352.x

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1462-8902
686views
0downloads

Technical informations

Creation

17/12/2012 15:51:00

First validation

17/12/2012 15:51:00

Update

14/03/2023 19:55:29

Status update

14/03/2023 19:55:29

Last indexation

30/10/2024 08:20:40
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated